@article{MTMT:33897225,
	title = {Stretch-Induced Down-Regulation of HCN2 Suppresses Contractile Activity},
	url = {https://m2.mtmt.hu/api/publication/33897225},
	author = {Kola, Job Baffin and Turarova, Botagoz and Csige, Dóra and Sipos, Ádám and Fodor-Varga, Luca Anna and Gergely, Bence and Refai, Farah Al and Uray, Iván and Docsa, Tibor and Uray (Davis), Karen L.},
	doi = {10.3390/molecules28114359},
	journal-iso = {MOLECULES},
	journal = {MOLECULES},
	volume = {28},
	unique-id = {33897225},
	issn = {1420-3049},
	abstract = {Although hyperpolarization-activated and cyclic nucleotide-gated 2 channels (HCN2) are expressed in multiple cell types in the gut, the role of HCN2 in intestinal motility is poorly understood. HCN2 is down-regulated in intestinal smooth muscle in a rodent model of ileus. Thus, the purpose of this study was to determine the effects of HCN inhibition on intestinal motility. HCN inhibition with ZD7288 or zatebradine significantly suppressed both spontaneous and agonist-induced contractile activity in the small intestine in a dose-dependent and tetrodotoxin-independent manner. HCN inhibition significantly suppressed intestinal tone but not contractile amplitude. The calcium sensitivity of contractile activity was significantly suppressed by HCN inhibition. Inflammatory mediators did not affect the suppression of intestinal contractile activity by HCN inhibition but increased stretch of the intestinal tissue partially attenuated the effects of HCN inhibition on agonist-induced intestinal contractile activity. HCN2 protein and mRNA levels in intestinal smooth muscle tissue were significantly down-regulated by increased mechanical stretch compared to unstretched tissue. Increased cyclical stretch down-regulated HCN2 protein and mRNA levels in primary human intestinal smooth muscle cells and macrophages. Overall, our results suggest that decreased HCN2 expression induced by mechanical signals, such as intestinal wall distension or edema development, may contribute to the development of ileus.},
	year = {2023},
	eissn = {1420-3049},
	orcid-numbers = {Turarova, Botagoz/0000-0002-8969-4998; Refai, Farah Al/0000-0002-4673-9738}
}

@article{MTMT:33238498,
	title = {Full Body Surface Coverage with Water-Equivalent Bolus as Novel Technique for Total Body Irradiation before Hematopoietic Stem Cell Transplantation in Pediatric Acute Lymphoid Leukemia},
	url = {https://m2.mtmt.hu/api/publication/33238498},
	author = {Furka, Andrea and Nagy, Zsofia and Szabó, Imre and Fekete, Gábor and Kelemen, Ágnes and Bolobás, Gábor and Sebők, Gábriel and Molnár, Tünde and Árvai, János and Tornyi, Ilona and Kostyál, László and Révész, János and Hauser, Péter},
	doi = {10.3390/children9111740},
	journal-iso = {CHILDREN-BASEL},
	journal = {CHILDREN (BASEL)},
	volume = {9},
	unique-id = {33238498},
	abstract = {Background: Total body irradiation (TBI) 2 × 2 Gy for 3 consecutive days followed by chemotherapy for conditioning pediatric patients with acute lymphoid leukemia (ALL) before bone marrow transplantation is superior to chemo-conditioning alone. The globally used anterior-posterior/posterior-anterior (AP/PA) technique is the most referable method, but volumetric modulated arc therapy (VMAT) with modern linear accelerators is more precise in terms of ensuring better dose distribution, especially for skin, and higher protection of organs at risk, resulting in less side effects. Method: For TBI, a modern VMAT technique was used. Whole-body immobilization in the supine position was performed using a vacuum mattress with a full body coverage, with a water-equivalent bolus of 1 cm thickness. The design goal was to achieve dose inhomogeneity of less than ±10%. Results: From 2020 to 2022, we performed TBI for five pediatric patients with ALL, with full body bolus and VMAT, who later received hematopoietic stem cell transplantation. No acute complications related to TBI were observed during the treatment period with a median follow-up of 1.27 (0.43–2.11) years. Conclusion: Using full body water-equivalent bolus with VMAT for TBI provides a safe method for children with a better organ sparing in the short term follow-up.},
	year = {2022},
	eissn = {2227-9067},
	orcid-numbers = {Tornyi, Ilona/0000-0003-2165-4196; Hauser, Péter/0000-0002-8307-8975}
}

@article{MTMT:31239122,
	title = {Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma},
	url = {https://m2.mtmt.hu/api/publication/31239122},
	author = {Rini, Brian I and Plimack, Elizabeth R and Stus, Viktor and Gafanov, Rustem and Hawkins, Robert and Nosov, Dmitry and Pouliot, Frédéric and Alekseev, Boris and Soulières, Denis and Melichar, Bohuslav and Vynnychenko, Ihor and Kryzhanivska, Anna and Bondarenko, Igor and Azevedo, Sergio J and Borchiellini, Delphine and Szczylik, Cezary and Markus, Maurice and McDermott, Raymond S and Bedke, Jens and Tartas, Sophie and Chang, Yen-Hwa and Tamada, Satoshi and Shou, Qiong and Perini, Rodolfo F and Chen, Mei and Atkins, Michael B and Powles, Thomas},
	doi = {10.1056/NEJMoa1816714},
	journal-iso = {NEW ENGL J MED},
	journal = {NEW ENGLAND JOURNAL OF MEDICINE},
	volume = {380},
	unique-id = {31239122},
	issn = {0028-4793},
	abstract = {The combination of pembrolizumab and axitinib showed antitumor activity in a phase 1b trial involving patients with previously untreated advanced renal-cell carcinoma. Whether pembrolizumab plus axitinib would result in better outcomes than sunitinib in such patients was unclear.In an open-label, phase 3 trial, we randomly assigned 861 patients with previously untreated advanced clear-cell renal-cell carcinoma to receive pembrolizumab (200 mg) intravenously once every 3 weeks plus axitinib (5 mg) orally twice daily (432 patients) or sunitinib (50 mg) orally once daily for the first 4 weeks of each 6-week cycle (429 patients). The primary end points were overall survival and progression-free survival in the intention-to-treat population. The key secondary end point was the objective response rate. All reported results are from the protocol-specified first interim analysis.After a median follow-up of 12.8 months, the estimated percentage of patients who were alive at 12 months was 89.9% in the pembrolizumab-axitinib group and 78.3% in the sunitinib group (hazard ratio for death, 0.53; 95% confidence interval [CI], 0.38 to 0.74; P<0.0001). Median progression-free survival was 15.1 months in the pembrolizumab-axitinib group and 11.1 months in the sunitinib group (hazard ratio for disease progression or death, 0.69; 95% CI, 0.57 to 0.84; P<0.001). The objective response rate was 59.3% (95% CI, 54.5 to 63.9) in the pembrolizumab-axitinib group and 35.7% (95% CI, 31.1 to 40.4) in the sunitinib group (P<0.001). The benefit of pembrolizumab plus axitinib was observed across the International Metastatic Renal Cell Carcinoma Database Consortium risk groups (i.e., favorable, intermediate, and poor risk) and regardless of programmed death ligand 1 expression. Grade 3 or higher adverse events of any cause occurred in 75.8% of patients in the pembrolizumab-axitinib group and in 70.6% in the sunitinib group.Among patients with previously untreated advanced renal-cell carcinoma, treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progression-free survival, as well as a higher objective response rate, than treatment with sunitinib. (Funded by Merck Sharp & Dohme; KEYNOTE-426 ClinicalTrials.gov number, NCT02853331.).},
	year = {2019},
	eissn = {1533-4406},
	pages = {1116-1127},
	orcid-numbers = {Horváth, Zsolt/0000-0002-5376-7737; Bodoky, György/0000-0002-5659-2020; Géczi, Lajos/0000-0001-7432-2043}
}

@misc{MTMT:31121921,
	title = {Az MMP-9, TIMP-1 és TIMP-2 viselkedése colorectalis carcinomában, Coloproctológiai Szekció és Sebészeti Endoszkópos Szekciójának 2019. évi közös Kongresszusa, Siófok.},
	url = {https://m2.mtmt.hu/api/publication/31121921},
	author = {Barabás, Loránd and Gráf, László and Garam, Nóra and Kocsis, Judit and Prohászka, Zoltán and István, Gábor and Herszényi, László},
	unique-id = {31121921},
	year = {2019},
	orcid-numbers = {Barabás, Loránd/0000-0001-7246-2739; Garam, Nóra/0000-0002-1959-4473; Kocsis, Judit/0000-0002-6110-9750; Prohászka, Zoltán/0000-0003-1761-7982}
}

@article{MTMT:30915378,
	title = {Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck. A randomised phase II study.},
	url = {https://m2.mtmt.hu/api/publication/30915378},
	author = {Forster, Martin D and Dillon, Magnus T and Kocsis, Judit and Remenár, Éva and Pajkos, Gabor and Rolland, Frederic and Greenberg, Jonathan and Harrington, Kevin J},
	doi = {10.1016/j.ejca.2019.08.017},
	journal-iso = {EUR J CANCER},
	journal = {EUROPEAN JOURNAL OF CANCER},
	volume = {123},
	unique-id = {30915378},
	issn = {0959-8049},
	keywords = {Recurrence; clinical trial; CETUXIMAB; Phase II; Metastatic; Squamous cell carcinoma of the head and neck; Heregulin; Patritumab},
	year = {2019},
	eissn = {1879-2995},
	pages = {36-47},
	orcid-numbers = {Kocsis, Judit/0000-0002-6110-9750}
}

@article{MTMT:30482090,
	title = {The Impact of Supply Chain Integration and Internal Control on Financial Performance in the Jordanian Banking Sector},
	url = {https://m2.mtmt.hu/api/publication/30482090},
	author = {Pakurár, Miklós and Haddad, Hossam and Nagy, János and Popp, József and Oláh, Judit},
	doi = {10.3390/su11051248},
	journal-iso = {SUSTAINABILITY-BASEL},
	journal = {SUSTAINABILITY},
	volume = {11},
	unique-id = {30482090},
	year = {2019},
	eissn = {2071-1050},
	orcid-numbers = {Popp, József/0000-0003-0848-4591; Oláh, Judit/0000-0003-2247-1711}
}

@article{MTMT:30450395,
	title = {The Service Quality Dimensions that Affect Customer Satisfaction in the Jordanian Banking Sector},
	url = {https://m2.mtmt.hu/api/publication/30450395},
	author = {Pakurár, Miklós and Haddad, Hossam and Nagy, János and Popp, József and Oláh, Judit},
	doi = {10.3390/su11041113},
	journal-iso = {SUSTAINABILITY-BASEL},
	journal = {SUSTAINABILITY},
	volume = {11},
	unique-id = {30450395},
	year = {2019},
	eissn = {2071-1050},
	orcid-numbers = {Popp, József/0000-0003-0848-4591; Oláh, Judit/0000-0003-2247-1711}
}

@article{MTMT:30391276,
	title = {Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study},
	url = {https://m2.mtmt.hu/api/publication/30391276},
	author = {Cohen, Ezra E W and Soulières, Denis and Le Tourneau, Christophe and Dinis, José and Licitra, Lisa and Ahn, Myung-Ju and Soria, Ainara and Machiels, Jean-Pascal and Mach, Nicolas and Mehra, Ranee and Burtness, Barbara and Zhang, Pingye and Cheng, Jonathan and Swaby, Ramona F and Harrington, Kevin J},
	doi = {10.1016/S0140-6736(18)31999-8},
	journal-iso = {LANCET},
	journal = {LANCET},
	volume = {393},
	unique-id = {30391276},
	issn = {0140-6736},
	abstract = {There are few effective treatment options for patients with recurrent or metastatic head-and-neck squamous cell carcinoma. Pembrolizumab showed antitumour activity and manageable toxicity in early-phase trials. We aimed to compare the efficacy and safety of pembrolizumab versus standard-of-care therapy for the treatment of head-and-neck squamous cell carcinoma.We did a randomised, open-label, phase 3 study at 97 medical centres in 20 countries. Patients with head-and-neck squamous cell carcinoma that progressed during or after platinum-containing treatment for recurrent or metastatic disease (or both), or whose disease recurred or progressed within 3-6 months of previous multimodal therapy containing platinum for locally advanced disease, were randomly assigned (1:1) in blocks of four per stratum with an interactive voice-response and integrated web-response system to receive pembrolizumab 200 mg every 3 weeks intravenously or investigator's choice of standard doses of methotrexate, docetaxel, or cetuximab intravenously (standard-of-care group). The primary endpoint was overall survival in the intention-to-treat population. Safety was analysed in the as-treated population. This trial is registered with ClinicalTrials.gov, number NCT02252042, and is no longer enrolling patients.Between Dec 24, 2014, and May 13, 2016, 247 patients were randomly allocated to pembrolizumab and 248 were randomly allocated to standard of care. As of May 15, 2017, 181 (73%) of 247 patients in the pembrolizumab group and 207 (83%) of 248 patients in the standard-of-care group had died. Median overall survival in the intention-to-treat population was 8·4 months (95% CI 6·4-9·4) with pembrolizumab and 6·9 months (5·9-8·0) with standard of care (hazard ratio 0·80, 0·65-0·98; nominal p=0·0161). Fewer patients treated with pembrolizumab than with standard of care had grade 3 or worse treatment-related adverse events (33 [13%] of 246 vs 85 [36%] of 234). The most common treatment-related adverse event was hypothyroidism with pembrolizumab (in 33 [13%] patients) and fatigue with standard of care (in 43 [18%]). Treatment-related death occurred in four patients treated with pembrolizumab (unspecified cause, large intestine perforation, malignant neoplasm progression, and Stevens-Johnson syndrome) and two patients treated with standard of care (malignant neoplasm progression and pneumonia).The clinically meaningful prolongation of overall survival and favourable safety profile of pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma support the further evaluation of pembrolizumab as a monotherapy and as part of combination therapy in earlier stages of disease.Merck Sharp & Dohme, a subsidiary of Merck & Co.},
	year = {2019},
	eissn = {1474-547X},
	pages = {156-167},
	orcid-numbers = {Kocsis, Judit/0000-0002-6110-9750}
}

@article{MTMT:3275013,
	title = {Assessment of the Role of Everolimus Therapy in Patients with Renal Cell Carcinoma Based on Daily Routine and Recent Research Results},
	url = {https://m2.mtmt.hu/api/publication/3275013},
	author = {Maráz, Anikó and Csejtei, A and Kocsis, Judit and Szűcs, Miklós and Kahán, Zsuzsanna and Bodoky, György and Dank, Magdolna and Mangel, László Csaba and Révész, János and Varga, Zoltán and Géczi, Lajos},
	doi = {10.1007/s12253-017-0317-0},
	journal-iso = {PATHOL ONCOL RES},
	journal = {PATHOLOGY AND ONCOLOGY RESEARCH},
	volume = {25},
	unique-id = {3275013},
	issn = {1219-4956},
	year = {2019},
	eissn = {1532-2807},
	pages = {149-156},
	orcid-numbers = {Maráz, Anikó/0000-0002-2018-8413; Kocsis, Judit/0000-0002-6110-9750; Szűcs, Miklós/0000-0003-3576-8637; Kahán, Zsuzsanna/0000-0002-5021-8775; Bodoky, György/0000-0002-5659-2020; Dank, Magdolna/0000-0002-4442-8733; Varga, Zoltán/0000-0001-8537-6282; Géczi, Lajos/0000-0001-7432-2043}
}

@article{MTMT:31337984,
	title = {Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with RAS-Mutated Hepatocellular Carcinoma},
	url = {https://m2.mtmt.hu/api/publication/31337984},
	author = {Lim, Ho Yeong and Merle, Philippe and Weiss, Karl Heinz and Yau, Thomas and Ross, Paul and Mazzaferro, Vincenzo and Blanc, Jean-Frederic and Ma, Yuk Ting and Yen, Chia Jui and Kocsis, Judit and Choo, Su Pin and Sukeepaisarnjaroen, Wattana and Gerolami, Rene and Dufour, Jean-Francois and Gane, Edward J. and Ryoo, Baek-Yeol and Peck-Radosavljevic, Markus and Thong, Dao and Yeo, Winnie and Lamlertthon, Wisut and Thongsawat, Satawat and Teufel, Michael and Roth, Katrin and Reis, Diego and Childs, Barrett H. and Krissel, Heiko and Llovet, Josep M.},
	doi = {10.1158/1078-0432.CCR-17-3588},
	journal-iso = {CLIN CANCER RES},
	journal = {CLINICAL CANCER RESEARCH},
	volume = {24},
	unique-id = {31337984},
	issn = {1078-0432},
	year = {2018},
	eissn = {1557-3265},
	pages = {4650-4661},
	orcid-numbers = {Kocsis, Judit/0000-0002-6110-9750}
}